摘要
BackgroundNumerous studies have reported that long non-coding RNAs (lncRNAs) play important roles in immune-related pathways in cancer. However, immune-related lncRNAs and their roles in predicting immunotherapeutic response and prognosis of non-small cell lung cancer (NSCLC) patients treated with immunotherapy remain largely unexplored. MethodsTranscriptomic data from NSCLC patients were used to identify novel lncRNAs by a custom pipeline. ImmuCellAI was utilized to calculate the infiltration score of immune cells. The marker genes of immunotherapeutic response-related (ITR)-immune cells were used to identify immune-related (IR)-lncRNAs. A co-expression network was constructed to determine their functions. LASSO and multivariate Cox analyses were performed on the training set to construct an immunotherapeutic response and immune-related (ITIR)-lncRNA signature for predicting the immunotherapeutic response and prognosis of NSCLC. Four independent datasets involving NSCLC and melanoma patients were used to validate the ITIR-lncRNA signature. ResultsIn total, 7,693 novel lncRNAs were identified for NSCLC. By comparing responders with non-responders, 154 ITR-lncRNAs were identified. Based on the correlation between the marker genes of ITR-immune cells and lncRNAs, 39 ITIR-lncRNAs were identified. A co-expression network was constructed and the potential functions of 38 ITIR-lncRNAs were annotated, most of which were related to immune/inflammatory-related pathways. Single-cell RNA-seq analysis was performed to confirm the functional prediction results of an ITIR-lncRNA, LINC01272. Four-ITIR-lncRNA signature was identified and verified for predicting the immunotherapeutic response and prognosis of NSCLC. Compared with non-responders, responders had a lower risk score in both NSCLC datasets (P<0.05). NSCLC patients in the high-risk group had significantly shorter PFS/OS time than those in the low-risk group in the training and testing sets (P<0.05). The AUC value was 1 of responsiveness in the training set. In melanoma validation datasets, patients in the high-risk group also had significantly shorter OS/PFS time than those in the low-risk group (P<0.05). The ITIR-lncRNA signature was an independent prognostic factor (P<0.001). ConclusionThousands of novel lncRNAs in NSCLC were identified and characterized. In total, 39 ITIR-lncRNAs were identified, 38 of which were functionally annotated. Four ITIR-lncRNAs were identified as a novel ITIR-lncRNA signature for predicting the immunotherapeutic response and prognosis in NSCLC patients treated with immunotherapy.
学科与关键词
- Identification of Prognostic Model Based on Immune-Related LncRNAs in Stage I-III Non-Small Cell Lung CancerLi, Qiaxuan; Yao, Lintong; Lin, Zenan; Li, Fasheng; Xie, Daipeng; Li, Congsen; Zhan, Weijie; Lin, Weihuan; Huang, Luyu; Wu, Shaowei; Zhou, Haiyu*Frontiers in Oncology, 2021, 11: 706616.被引 1
- Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinomaCao, Kui; Liu, Mingdong; Ma, Keru; Jiang, Xiangyu; Ma, Jianqun*; Zhu, Jinhong*Cancer Immunology, Immunotherapy, 2022, 71(6): 1295-1311.被引 14
- Construction of a 5 immune-related lncRNA-based prognostic model of NSCLC via bioinformaticsHuang, Ya-jie*; Huang, Chang-jieMedicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2021, 100(37): e27222.被引 3
